Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases.
Neurodegenerative diseases are characterized by premature neuronal loss in specific brain regions. During the past decades our knowledge on molecular mechanisms underlying neurodegeneration has increased immensely and resulted in promising drug candidates that might slow down or even stop the neuronal loss. These advances have put a strong focus on the development of diagnostic tools for early or pre-clinical detection of the disorders. In this review we discuss our experience in the field of neuroproteomics/peptidomics, with special focus on biomarker discovery studies that have been performed on CSF samples from well-defined patient and control populations.
Westman-Brinkmalm
Ann
A
Institute of Neuroscience and Physiology, Department of Psychiatry and Neuochemistry, The Sahlgrenska Academy at Goteborg University, Sweden. ann.brinkmalm@neuro.gu.se
Ruetschi
Ulla
U
Portelius
Erik
E
Andreasson
Ulf
U
Brinkmalm
Gunnar
G
Karlsson
Gosta
G
Hansson
Sara
S
Zetterberg
Henrik
H
Blennow
Kaj
K
D015415:Biomarkers / Q000134:cerebrospinal fluid*; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D013058:Mass Spectrometry / Q000379:methods; D019636:Neurodegenerative Diseases / Q000134:cerebrospinal fluid*; D010455:Peptides / Q000378:metabolism*; D040901:Proteomics
D015415:Biomarkers; D010455:Peptides